Maria Buti, EASL ILC 2022: Impact of bulevirtide on patient-reported outcomes
MYR301 (NCT03852719) is a phase 3 study evaluating the long-term efficacy and safety of bulevirtide in people living with chronic hepatitis delta infection (CHD). In this interview, Prof. Maria Buti (Vall d’Hebron University Hospital, Barcelona, Spain) discusses the results from the exploratory analysis of MYR301, investigating the health-related quality of life (HRQOL) benefits of treatment with bulevirtide.
Questions
1. Why has it been so challenging to find effective treatment options for chronic hepatitis delta (CHD)? (0.12)
2. Could you give us a brief overview of the clinical data leading to the EMA’s conditional approval of bulevirtide for the treatment of CHD? (0:42)
3. Could you tell us a little about the MYR301 study and its primary findings? (2:35)
4. What were patient-reported outcomes investigated in the MYR301 study and what were the findings? (3:29)
5. What questions remain unanswered and what further research is planned? (4:45)
Disclosures: Maria Buti has acted as an advisor for Gilead, Abbvie and Janssen.
Support: Interview supported by Touch Medical Media.
Recorded as a highlight of EASL ILC 2022
Click here for more related content.
